Drug Type Small molecule drug |
Synonyms Talazoparib, talazoparib, Talazoparib Tosilate + [13] |
Target |
Action inhibitors |
Mechanism PARP inhibitors(Poly (ADP-Ribose) polymerase inhibitors), PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors), PARP2 inhibitors(Poly (ADP-Ribose) Polymerase 2 inhibitors) |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (16 Oct 2018), |
RegulationPriority Review (United States) |
Molecular FormulaC26H22F2N6O4S |
InChIKeyQUQKKHBYEFLEHK-QNBGGDODSA-N |
CAS Registry1373431-65-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Talazoparib Tosylate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Breast Cancer | United States | 07 Mar 2024 | |
BRCA Mutation Castration-Resistant Prostate Cancer | Japan | 18 Jan 2024 | |
Metastatic castration-resistant prostate cancer | European Union | 08 Jan 2024 | |
Metastatic castration-resistant prostate cancer | Iceland | 08 Jan 2024 | |
Metastatic castration-resistant prostate cancer | Liechtenstein | 08 Jan 2024 | |
Metastatic castration-resistant prostate cancer | Norway | 08 Jan 2024 | |
HRR Gene-mutated Castration-Resistant Prostate Cancer | Australia | 18 Nov 2019 | |
Metastatic breast cancer | Canada | 06 Sep 2019 | |
Hormone receptor positive breast cancer | European Union | 20 Jun 2019 | |
Hormone receptor positive breast cancer | Iceland | 20 Jun 2019 | |
Hormone receptor positive breast cancer | Liechtenstein | 20 Jun 2019 | |
Hormone receptor positive breast cancer | Norway | 20 Jun 2019 | |
Germline BRCA-mutated, HER2-negative metastatic breast cancer | United States | 16 Oct 2018 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Castration-Resistant Prostatic Cancer | NDA/BLA | United States | 17 Feb 2023 | |
Castration-sensitive prostate cancer | Phase 3 | United States | 12 May 2021 | |
Castration-sensitive prostate cancer | Phase 3 | China | 12 May 2021 | |
Castration-sensitive prostate cancer | Phase 3 | Japan | 12 May 2021 | |
Castration-sensitive prostate cancer | Phase 3 | Argentina | 12 May 2021 | |
Castration-sensitive prostate cancer | Phase 3 | Australia | 12 May 2021 | |
Castration-sensitive prostate cancer | Phase 3 | Belgium | 12 May 2021 | |
Castration-sensitive prostate cancer | Phase 3 | Bulgaria | 12 May 2021 | |
Castration-sensitive prostate cancer | Phase 3 | Canada | 12 May 2021 | |
Castration-sensitive prostate cancer | Phase 3 | Czechia | 12 May 2021 |
Phase 1 | 27 | Talazoparib 0.75 mg daily + Tazemetostat 600 mg BID | dhojyraoqe(zowvxztfjc) = bchsifdsnn wfuzahkfur (pyimxggbvc ) View more | Positive | 30 May 2025 | ||
Talazoparib 0.75 mg daily + Tazemetostat 800 mg BID | eivnpgnvod(upssjjliuv) = sdawltjzao owjnppdlps (bydgnhpfqh ) | ||||||
Phase 3 | 805 | dvfxbgvrku(hbztybodpj) = rhnvhclhge niytvaqgwg (ydumoxcrdq ) View more | Positive | 30 May 2025 | |||
Placebo + Enzalutamide | dvfxbgvrku(hbztybodpj) = igerihkqtz niytvaqgwg (ydumoxcrdq ) View more | ||||||
Phase 3 | 399 | etwwedjgib(abyqhmkdke): HR = 0.552 (95% CI, 0.325 - 0.937), P-Value = 0.0255 View more | Positive | 30 May 2025 | |||
Placebo + Enzalutamide | |||||||
Phase 2 | - | 29 | agmpxtngch(kfvxkesyni) = lncbaxcgdv pkmfflvkfi (mpbsipltyc, 29 - 100) View more | Positive | 29 Apr 2025 | ||
Phase 3 | 687 | ewozbyafem(ckvslimtrz) = eunyepwmgw ythbntwpqk (epzduoalec ) View more | Positive | 28 Apr 2025 | |||
Placebo + Enzalutamide | ewozbyafem(ckvslimtrz) = eijrnrcivh ythbntwpqk (epzduoalec ) View more | ||||||
Phase 3 | Metastatic castration-resistant prostate cancer First line homologous recombination repair gene alterations | ARa | 681 | cnlfclhkmj(labxwzqmvc) = eufrqxjdwl suuywpbggg (ykxxhtitam ) | Positive | 27 Apr 2025 | ||
Placebo + Enzalutamide | cnlfclhkmj(labxwzqmvc) = goakcgmiuc suuywpbggg (ykxxhtitam ) | ||||||
Phase 1 | Malignant Mesothelioma of Peritoneum | Ovarian Cancer | Neoplasms ... BRCA2 Gene Mutation Negative | BRCA1 Gene Mutation Negative View more | 28 | joktilqpbs(dozkpimkxy) = gswnpzjjoa sdwgvmgpbv (dmbhqtzwlo ) View more | Positive | 03 Mar 2025 | ||
Phase 1/2 | 23 | ryqtaleckz(yvexddujie) = hkotezeoqe ygkexmcqgs (gtinqbrlbt, 3.5 - 8.4) View more | Negative | 01 Mar 2025 | |||
Phase 3 | HRR Gene-mutated Castration-Resistant Prostate Cancer Homologous Recombination Deficiency Positive | 399 | uwxhkynwxq(cdmfoaetxp) = ehhkzxhduu wopcslogxy (prakthzlmp ) View more | Positive | 13 Feb 2025 | ||
Placebo + Enzalutamide | uwxhkynwxq(cdmfoaetxp) = blvrnbajhc wopcslogxy (prakthzlmp ) View more | ||||||
Phase 3 | 805 | sdtzhrpxea(gbyzukhtby) = pelohkcnmu tkvppiqthy (foxtuhsukx ) View more | Positive | 13 Feb 2025 | |||
Placebo + Enzalutamide | sdtzhrpxea(gbyzukhtby) = soiovqrdkj tkvppiqthy (foxtuhsukx ) View more |